Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments

(2019) Ivenise Carrero et al.   ONCOGENE

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy

(2019) Gui-Zhen Wang et al.   Nature Communications

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

(2019) Yi-Long Wu et al.   Journal of Thoracic Oncology

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation

(2019) Mercedes Segovia et al.   CANCER CELL

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database

(2019) Gaurav Singal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study

(2019) Antonella Argentiero et al.   Cancers

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review

(2018) Hélène Babey et al.   Expert Review of Anticancer Therapy

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization

(2018) Fei Zhao et al.   IMMUNITY

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis

(2018) Bingjia Li et al.   OncoTargets and Therapy

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

(2018) Chee Khoon Lee et al.   JAMA Oncology

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

(2018) Antoni Ribas et al.   CELL

Cigarette Smoke–Induced Emphysema Exhausts Early Cytotoxic CD8+T Cell Responses against Nascent Lung Cancer Cells

(2018) Dimitra Kerdidani et al.   JOURNAL OF IMMUNOLOGY

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

(2018) Fabrice Barlesi et al.   LANCET ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

(2018) S. N. Gettinger et al.   Nature Communications

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

(2018) Terry L. Ng et al.   CANCER

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

(2018) Junghoon Shin et al.   Cancer Research and Treatment

Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients

(2018) Patrizia Leone et al.   OncoImmunology

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

(2018) Vivek Verma et al.   Journal for ImmunoTherapy of Cancer

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy

(2017) Chunkit Fung et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

(2017) Ramaswamy Govindan et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis

(2017) Kentaro Inamura et al.   LUNG CANCER

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma

(2017) S. Andrew Skillington et al.   JAMA Otolaryngology-Head & Neck Surgery

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

(2016) Takaaki Tokito et al.   EUROPEAN JOURNAL OF CANCER

Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer

(2016) Linda E. Kelemen et al.   GYNECOLOGIC ONCOLOGY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

(2016) Satoshi Igawa et al.   ONCOLOGY

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy

(2016) Steffen Filskov Sorensen et al.   Translational Oncology

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing

(2015) P. Leone et al.   BLOOD

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

(2015) Cheng Lin et al.   Clinical Lung Cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation

(2014) Luciana Cavalheiro Marti et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE